HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumor Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC) 🎙️Dr. Anne C. Chiang 🔢3837RO 🎯At Recommended Ph3 Dose (1.8mg/kg Q3W, 2L+, n=41) 🎯Overall: ORR 56%, mOS 12.4mo 🎯2L Subset (n=17): ORR 82%, mOS 14.3mo 🎯100% ctDNA Clearance at C3D1 Linked to Better PFS/OS ☑️NCT05599984 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 1 · 1 赞 · 0 回复 · 0 转发
会议摘要
NCT05599984NCT05599984按 - **标题 / Title：** Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors 对上
- **标题 / Title：** Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com